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Emerging treatment paradigms like targeting the tumor microenvironment and/or dosing as part 
of a metronomic regimen are anticipated to produce better outcomes in ovarian cancer but 
current drug delivery systems are lacking.  We have designed and evaluated paclitaxel (PTX) 
and rapamycin (RAP) micellar systems that can be tailored for various dosing regimens and 
target tumor microenvironment.  Individual and mixed PTX:RAP (MIX-M) micelles are prepared 
by conjugating drugs to a poly(ethylene glycol)-block-poly(β-benzyl L-aspartate) using a pH-
sensitive linker. The micelles release the drug(s) at pH 5.5 indicating preferential release in the 
acidic endosomal/lysosomal environment.  Micelles exhibit anti-proliferative effects in ovarian 
cell cancer lines (SKOV-3 and ES2) and an endothelial cell line (HUVEC) with the MIX-M being 
synergistic. The micelles also inhibited endothelial migration and tube formation. In healthy 
mice, micelles at 60 mg/kg/drug demonstrated no acute toxicity over 21 days.  ES2 xenograft 
model efficacy studies at 20 mg/kg/drug dosed every 4 days and evaluated at 21 days indicate 
that the individual micelles exhibit anti-angiogenic effects, while the MIX-M exhibited both anti-
angiogenic and apoptotic induction that results in significant tumor volume reduction.  Based on 
our results, MIX-M micelles can be utilized to achieve synergistic apoptotic and anti-angiogenic 
effects when treated at frequent low doses.  
  
1. Introduction 
Epithelial ovarian cancer is the most lethal gynecologic malignancy in the United States1 due to 
the complexity of the disease which results in a high rate of recurrence and the development of 
chemo-resistant disease. The response rate for recurrent ovarian cancer is 30% for most 
patients and the rate is even lower in those women who become refractory to platinum 
compounds2. Current chemotherapeutic strategies for treatment rely on maximum tolerated 
doses (MTD) of taxanes and platinums administered every 3 weeks3, 4.  This allows for an 
extended drug-free period for the patient to recover from chemotherapy-induced adverse 
effects. However, this drug-free interval can also result in tumor reinitiating growth5 through the 
mobilization of circulating endothelial progenitor cells and results in tumor neovascularization 
and lower longer term prognosis3.  MTD treatment in advanced ovarian cancer (stages III and 
IV) also results in frequent discontinuation of therapy because of toxicity and/or development of 
resistance6, 7.  
New advances in tumor biology suggest targeting the tumor microenvironment and not just the 
cancer cells8, 9. This is backed by emerging clinical data that indicates that antiangiogenic 
agents can induce ovarian tumor regression; however, resistance and toxicity develop quickly10-
14. Newer, therapeutic paradigms like metronomic therapy has been developed to target tumor 
cells and microenvironment.  Metronomic therapy as defined by the administration of 
chemotherapeutic  agents at doses significantly below the MTD, given at regular, more frequent 
time intervals with no prolonged drug-free breaks15-17.  The basis of the metronomic dosing 
regimen (MR) lies in shifting cancer treatment from an acute response (MTD treatment) to 
management as a chronic condition. The second goal of MR is to target not only the cancer 
cells directly but also the surrounding new vasculature that emerges through angiogenesis3, 16, 
18, 19. In addition, new studies have shown that MR induces other mechanisms of action 
including antitumor immune responses and direct anticancer effects. Therefore, MR is now 
considered to be a form of multiple-targeted chemotherapy that has a profound effect on the 
tumor microenvironment20. Many studies have demonstrated that patients with advanced cancer 
who developed resistance to MTD chemotherapy could still benefit from iterative dosing of 
distinct cytotoxic drugs utilizing MR, at a tenth to a third of the MTD21.  
Currently no drug delivery systems exist for the treatment of ovarian cancer that can be adapted 
for conventional and emerging treatment paradigms without developing resistance and/or 
inducing toxicity. Agents commonly used in treating ovarian cancer include platinums and 
taxanes, while platinums have shown efficacy at MTD currently no data exists indicating 
platinums have any effect in inhibiting angiogenesis and affecting tumor microenvironment.  
Taxanes like paclitaxel (PTX) and other cancer cytotoxic agents like mammalian target of 
rapamycin (mTOR) inhibitors, have demonstrated both cytotoxic and secondary antiangiogenic 
effects in tumor tissues22, 23.  However, these dual capacities are not fully manifested, due to 
limitations in dosing regimens and available drug formulations18, 22, 24, 25. PTX, a taxane, is a 
cytotoxic agent that causes stabilization of microtubule dynamics leading to cancer cell death26, 
and can also inhibit endothelial cell proliferation, tube formation and migration27, 28, thereby 
inhibiting the angiogenic process 29. Rapamycin (RAP), an mTOR inhibitor, is another cytotoxic 
agent that can inhibit cancer cell proliferation and angiogenesis. RAP exerts its effect by acting 
directly on mTOR, a key kinase acting downstream of the activation of PI3K30, leading to the 
inhibition of VEGF expression and blocking the endothelial to mesenchymal transition. Evidence 
also links the inhibition of mTOR to the suppression of proangiogenic factors through down 
regulation of hypoxia mediated pathways22, 31, 32. 
 
Conventional dosing regimens of PTX and RAP are unable to sustain cytotoxic and 
antiangiogenic effects during required recovery periods. While MR with a single agent has 
sustained antiangiogenic effects due to continual treatment, cytotoxic effects are not seen. 
Taxol®, PTX’s commercial formulation, cannot be used as an antiangiogenic agent because the 
drug is entrapped in the formulation leading to the reduction in PTX antiangiogenic activity.  
RAP is currently available as an oral drug product, for immune suppression in transplant 
patients, and is being investigated in several clinical trials as a chemotherapeutic agent 20 yet, 
no i.v. formulations of RAP currently exist. Several recent publications, ours and others, have 
demonstrated that that PTX and RAP when dosed together have strong synergistic effects in 
vitro and in vivo33.  Inhibition of mTOR using RAP has also been shown to increase and prolong 
sensitivity of various cancer cells to PTX34-36.  A drug delivery system capable of achieving the 
required cytotoxic and antiangiogenic effects through synergistic combinations of PTX and RAP 
may provide the necessary versatility needed to adapt to existing and emerging treatment 
paradigms without the current drawbacks of toxicity and resistance. 
Polymeric micelles have the capacity to deliver multiple agents simultaneously and release of 
these molecules can be tailored through physical entrapment of chemical conjugation37, 38. 
Amphiphilic block copolymers (ABCs) spontaneously assemble into polymeric micelles that are 
nanoscopic with a core/shell architecture37, 38.  Poly(ethylene glycol)-block-poly(β-benzyl L-
aspartate) (PEG-PBLA) is an ABC that has been used as a starting point for polymeric micelles 
to deliver various chemotherapeutics39, 40.  We have developed new pH-sensitive conjugated 
polymeric micellar nanocarriers that can be adapted for the delivery of chemotherapeutic 
agents41, 42. The rate of drug release can be tuned, using different linkers, and allows the 
formation of mixed micelles containing multiple drugs in the core for simultaneously delivery 
within the targeted cell to achieve additive/synergistic effects (Fig. 1)42-45. Therefore, we 
hypothesize that a polymeric micellar system that can simultaneously deliver PTX and RAP to 
provide both synergistic cytotoxic and antiangiogenic effects in an ovarian cancer mouse model 
can be adapted for conventional or emerging therapeutic strategies.  
 Fig. 1. Formation of PTX & RAP individual and mixed micelles (A). Theoretical pH-dependent 
drug release from micelles (B). Micelle accumulation in ovarian cancer cells and angiogenic 
vessels (C) 
2. Materials & Methods 
2.1. Materials 
α-aminopropyl-ω-methoxy-poly(ethylene glycol) (PEG-NH2) (Mn 12,000 g/mol, PDI = 1.03) was 
purchased from NOF America Corporation (White Plains, NY). PTX and RAP were obtained 
from LC laboratories Inc (Woburn, MA). Slide-A-Lyzer® dialysis cassettes (with a MWCO of 
20,000 Da) were obtained from Thermo Scientific Inc. (Fairlawn, NJ). SKOV-3 (Human 
Caucasian Ovarian Adenocarcinoma)46, ES2 (Human Ovarian Clear Cell Carcinoma, a distinct 
histopathologic subtype of epithelial ovarian cancer)46, 47, cell lines were purchased from 
American Type Culture Collection (Manassas, VA). Human Umbilical Vein Endothelial Cells 
(HUVEC)48 cells and endothelial growth medium 2 were purchased from PromoCell (Heidelberg, 
Germany). Cells were cultured as per the manufacturer instructions and all experiments were 
performed between passages 2 and 6.  CIM-Plates 16 for the migration assay were obtained 
from ACEA Biosciences Inc.( San Diego, CA), µ-Slide Angiogenesis ibiTreat were ordered form 
ibibi, LCC (Verona, WI).  Matrigel for the tube formation assay was purchased from BD 
Biosciences (San Jose, CA). Cleaved Caspase-3 Rabbit antibody was purchased form Cell 
Signaling Technology (Danvers MA). CD31 Rabbit polyclonal antibody was purchased from 
Abcam Inc. (Cambridge MA). Cy3-AffiniPure Donkey Anti-Rabbit IgG (H+L) antibody was 
purchased form Jackson Immune Research (West Grove, PA). Cell culture reagents, 
Fibronectin (Human Natural Corning) and disposables were purchased from VWR (Radnor, 
PA), Thermo Scientific (Fairlawn, NJ), or PromoCell (Heidelberg, Germany).  CellTiter-Blue® 
Cell Viability Assay kit was obtained from Promega Inc. (Madison, WI). All other materials and 
reagents were of analytical grade and were obtained from Sigma-Aldrich Inc (Milwaukee, WI) or 
Thermo Scientific (Fairlawn, NJ). 
2.2. Methods  
2.2.1. Synthesis and characterization of PEG-p(Asp-Hyd-LEV-PTX) or PEG-p(Asp-Hyd-
LEV-RAP) 
The schematic for the synthesis is presented in Fig. 2.  Fuchs-Farthing method49 is followed to 
synthesize the β-benzyl-L-aspartate N-carboxyanhydride (BLA-NCA) (1). β-benzyl L-aspartate 
(25 g, 112 mmole) is dried under vacuum for 3 h and is mixed with 0.3 equivalent of triphosgene 
(10 g, 33.6 mmol) and the mixture is dissolved in 120 mL anhydrous THF and the reaction is run 
at 40 oC for 24 h under Argon atmosphere.  Upon completion of the reaction, the solution 
becomes clear (indicative of BLA-NCA formation) and 300 mL of hexane is added to precipitate 
BLA-NCA (1) which is then purified by recrystallization from THF and hexane. 
PEG-PBLA is synthesized using previously described methods39, 40, 50, 51. The BLA-NCA (1) (1.7 
g, 6.82 mmol) is polymerized by ring opening initiated by the terminal primary amine group of 
PEG-NH2 (2) (2.0 g, 0.16 mmol). The reaction is performed in anhydrous DMSO (40 mL) under 
argon at 45 oC for 48 h. The resulting PEG-PBLA (3) is precipitated using diethyl ether and 
freeze dried from benzene. The next step in the synthesis is the preparation of PEG-p(Asp-Hyd) 
(PEG-HYD)  (4) by aminolysis reaction 41, 52-54. The reaction is carried out on PEG-PBLA (1.0 g, 
0.05 mmol) by dissolving it in anhydrous N,N-dimethylformamide (DMF) (20 mL).  Anhydrous 
hydrazine (1.2 eq with respect to benzyl groups) is added to the polymer solution and the 
reaction is carried out at 40 oC, under argon for 12 h.  The resulting PEG-HYD is precipitated in 
diethyl ether and freeze dried from benzene (4).  The third step of the reaction introduces the 
linker, levulinic acid (LEV), to the polymer backbone for subsequent drug attachment41, 42.  The 
hydrazine groups on the PEG-HYD (750 mg , 0.046 mmol) are reacted with the ketone group on 
the LEV (1.2 eq with respect to hydrazide group) in 15 mL of anhydrous DMSO to form PEG-
p(Asp-Hyd-LEV) (PEG-LEV) (5).  The reaction is carried out at 45 oC for 48 h, followed by 
precipitation of the PEG-LEV from diethyl ether.  Post precipitation the PEG-LEV is dissolved 
and dialyzed in DMF for purification, precipitated in diethyl ether and freeze dried from benzene. 
PTX or RAP conjugation is the final step in this reaction scheme. The reaction is carried out by 
dissolving PTX (1.57 g, 1.84. mmol) or RAP (2.00 g, 2.19 mmol) with PEG-LEV (1.00 g, LEV = 
1.84 mmol) in a co-solvent system consisting of dichloromethane (DCM): DMF (3:1) (30 mL) 
along with N,N'-diisopropylcarbodiimide (DIC; 0.29 g, 2.30 mmol) and 4-dimethylaminopyridine 
(DMAP; 0.12 g,  0.95 mmol). The reaction is allowed to proceed at 25 oC for 96 h and the 
resulting PEG-p(Asp-Hyd-LEV-PTX) (PEG-LEV-PTX)41, 42 or PEG-p(Asp-Hyd-LEV-RAP) (PEG-
LEV-RAP) (6) is collected by evaporating the DCM.  The residue is diluted in DMF and dialyzed 
against 1.0 L DMF (DMF is changed 3 times) using regenerated cellulose (MWCO: 6-8000 
g/mol).  The polymer is precipitation in diethyl ether and freeze dried from benzene.  For each 
step of the reaction the structure is confirmed by 1H NMR (400MHz, DMSO-d6), FT-IR and the 
molecular weight is assessed using gel permeation chromatography (GPC). The amount of drug 
conjugated is quantified by 1H NMR (400MHz, DMSO-d6), and Reversed-phase HPLC (RP-
HPLC).  
 
Fig. 2. Synthesis schematic for PEG-LEV-PTX41, 42 or PEG-LEV-RAP 
NMR measurements are performed on a DPX-400 NMR Spectrometer (Bruker Corp. Billerica, 
MA) at 400 MHz normal proton frequencies. The sample temperature is maintained at 80 oC for 
the duration of the measurement.  Acquisition parameters are adjusted on a case-by-case basis 
to provide adequate signal-to-noise and spectral resolution. All 1H spectra are referenced with 
respect to DMSO at 2.5 ppm. FT-IR measurements are performed on Nicolet iS5 Mid-Infrared 
FT-IR spectrometer equipped with iD5 Diamond ATR for Nicolet iS5 (Thermo Scientific. 
Waltham, MA) 
Gel permeation chromatography (GPC) analysis is performed for each of the synthesized 
polymers to evaluate the weight average molecular weight (Mw), the number average molecular 
weight (Mn), polydispersity index (PDI), Hydrodynamic Radius (Rh), intrinsic viscosity [η], and 
Mark-Houwinks constant α.  The GPC measurements are carried out using a Viscotek system 
equipped with Viscotek GPC Max VE 2001 solvent sample module, column oven 90-225 revH, 
Viscotek VE 3500 RI detector, and Viscotek 270 Dual Detectors (light scattering operating and 
viscometer detectors) (Malvern Instruments Inc., UK).  Tosho TSKgel G4000SW column (13 
µm, 450 Å silica, 7.5 mm ID x 30 cm) (Tosoh Bioscience LLC, King of Prussia, PA) with DMF 
stabilized with 10 mM LiBr as the eluting solvent at a flow rate of 1 mL/min is used.  The column 
is maintained at 30 °C for the duration of analysis. Polymers are solubilized in DMF at 
concentrations of 20 mg/mL and filtered through a 0.2 µm filter prior to injecting 100 µL for 
analysis.  Mw, Mn, PDI, [η] and α are computed using a triple detection method with a narrow 
polymethylmethacrylate (PMMA) standard (65,000 Da, PDI at 1.10, [η] of 0.245 dL/g and dn/dc 
of 0.057mL/g; Agilent Technologies., Santa Clara, CA). All measurements are performed in 
triplicate. The results are compiled using OmniSEC Software (Malvern Instruments Inc., UK) 
RP-HPLC is performed on a Shimadzu prominence HPLC system (Shimadzu, JP), equipped 
with a LC-20AT pump, SIL-20AC HT autosampler, CTO-20AC column oven, and a SPD-M20A 
diode array detector.  A Zorbax SB-C8 Rapid Resolution cartridge (4.6×75mm, 3.5 micron) 
(Agilent Technologies, Santa Clara, CA) is used to quantify the amount of conjugated PTX or 
RAP.  Run conditions include a mobile phase of Acetonitrile (ACN):Water (47:53) with 1% 
methanol and 0.1% H3PO4 run in isocratic mode at 1mL/min.  Injection volume of 10 µL is used 
and the column temperature is maintained at 40 oC with a run time of 8 min.  PTX and RAP are 
detected by UV at 3.3 min and 5.6 min respectively at wavelengths of 227 nm and 279 nm 
respectively. To quantify the amount of conjugated drug,  PEG-LEV-PTX or PEG-LEV-RAP, is 
incubated in 550 µL double distilled (DD) H2O, 400 µL ACN and 50 µL of 6 N Hydrochloric acid  
(PTX) or 5 N acetic acid (RAP) to ensure complete hydrolysis of the hydrazone bond and the 
release of PTX or RAP from the polymer backbone.  Post-incubation, the samples are 
centrifuged at 10,000 rpm for 3 min and filtered using a 0.45 µm nylon filter and injected into the 
column for analysis.  
2.2.2. Preparation and characterization of PTX micelles (PTX-M), RAP micelles (RAP-M), 
and PTX:RAP 1:1 molar ratio mixed micelles (MIX-M)  
To prepare individual micelles, PTX-M or RAP-M; PEG-LEV-PTX or PEG-LEV-RAP polymer at 
10 mg corresponding to, 4.4 µmol PTX or 4.3 µmol RAP respectively is dissolved in 1 mL of 
ACN and the resulting solution is placed in a 10 mL round bottom flask. The ACN is fully 
evaporated under vacuum (200 mbar) at 40 oC for 10 min.  The formed film is rehydrated in 1 
mL 10 mM phosphate buffer (pH 7.4) and the final micellar solution is filtered using a 0.45 µm 
nylon filter. The MIX-M are prepared similarly with 10 mg total of the polymer with 5 mg polymer 
corresponding to 2.4 µmol PTX and 5 mg polymer corresponding to, 2.2 µmol RAP to achieve a 
1:1 molar ratio of the two drugs.  PTX-M, RAP-M or MIX-M are assessed for loading by RP-
HPLC (section 2.2.1), size by dynamic light scattering (DLS) and drug release by dialysis.  
The hydrodynamic diameters of the micelles are calculated using a ZETASIZER Nano-ZS 
(Malvern Instruments Inc., UK) equipped with He-Ne laser (4mW, 633 nm) light source and 
scattering angle of 173o collection configuration to determine micelles mean diameters by this 
DLS technique.  All measurements are done in triplicate, and the data is presented as mean 
volume weighted diameters ± SD along with the corresponding polydispersity index (PDI). 
The prepared micelles are imaged with Transmission Electron Microscopy (TEM). Samples are 
prepared by placing 3 µL of the micellar solution onto the copper grid coated with carbon. After 
removing the excess solution using a filter paper, the grid is left to dry for 10 min. The samples 
are examined at 120 kV on FEI Tecnai Spirit TEM system. Images are acquired as 2048x2048 
pixel, 16-bit gray scale files using the FEI’s TEM Imaging & Analysis (TIA) interface on an Eagle 
2K CCD multi scan camera.  
In vitro PTX and/or RAP release from the PTX-M, RAP-M, or MIX-M is evaluated by dialysis of 
the micelles against 10 mM acetate (pH 5.5) or phosphate (pH 7.4) buffer.  Freshly prepared 2.5 
mL of each micelle are loaded into 3 mL dialysis cassettes with a MWCO of 20,000 Da.  This 
MWCO ensures free diffusion of the unconjugated drugs and dissociated polymer molecules. 
The cassettes are placed in 2.5 L of the buffer solution, which is changed every 3 h to ensure 
sink conditions.  Samples of 150 µL are withdrawn and replaced with equal volume of fresh 
buffer at 0, 0.5, 1, 2, 3, 6, 9, 12, and 24 h.  The samples are incubated in 400 µL ACN and 50 
µL of 6 N Hydrochloric acid (PTX) or 5 N acetic acid (RAP) to ensure complete release of PTX 
and RAP from the polymer backbone prior to analysis by RP-HPLC.  Data from three replicates 
is presented as mean percent (%) drug release ± SD. The data is further analyzed by curve 
fitting into a one phase exponential association using GraphPad Prism version 6.07 for 
Windows, GraphPad Software, La Jolla California, USA.  Based on the curve fitting, a half-life 
for the association (t1/2) and goodness of fit values (r2) for the average of the three replicates is 
presented. 
2.2.3. In vitro cell viability and combination index analysis studies in SKOV-3, ES2, and 
HUVEC cells 
Cell viability in the presence of PTX-M, R AP-M, and MIX-M is assessed in two ovarian cancer 
cell lines (SKOV-3 and ES2) and an endothelial cell line (HUVEC).  All cells are seeded in 96 
well plates at 5000 cells/well and are allowed to attach for 12 h (cancer cells) or 24 h (HUVEC).  
Post attachment cells are treated with 10 mM phosphate buffer (control), PEG-LEV directly 
dissolve in PBS at 100 nM (vehicle control) , PTX-M, RAP-M, or MIX-M (section 2.2) at dose 
ranges of 10 pM -10 µM (corresponding to PTX and/or RAP).  Treated and untreated cells are 
incubated for 72 h (cancer cells) or 48 h (HUVEC) at 37 oC in 5% CO2 atmosphere. Additionally 
the effect of PTX and/or RAP in DMSO on the viability of the same cells is assessed. PTX 
concentration ranges of 5 pM-500 µM while for RAP ranges of 5 nM-500 µM. Post-treatment cell 
treated with 20 µL/well Cell Titer Blue® and allowing the plates to incubate for 1.5 h at 37 oC.  
Post-incubation the cell viability is assessed by fluorescence at 560EX/590EM.  All experiments 
are performed in quadruplicate and data is presented as mean drug concentration at 50% 
growth inhibition (IC50) ± SD.  The IC50 values are calculated using the linearized median-effect 
plot with the CompuSyn software (Version 1.0, ComboSyn Inc., U.S.)55.  The same software is 
utilized to calculate the combination index (CI) values for the MIX-M combination.  Based on the 
Chou and Talay median-effect principle, CI values of <1, 1, and >1 are indicative of synergy, 
additivity, and antagonism respectively56.  The software calculates the fraction of cells affected 
(Fa) and correlates it with the CI, providing the ability to assess effects at various drug 
concentrations in the combination. The curve fitting of CI vs Fa for the average of four replicates 
is presented. 
2.2.4. In vitro real-time migration and tube formation studies in HUVECs 
HUVEC migration is assessed using the xCELLigence RTCA DP system (Roche Applied 
Sciences, Germany) which measures the change in electrical impedance (recorded as cell 
index number) as cells migrate from the apical to the basolateral chamber in response to a 
chemoattractant. To assess the migration, CIM-Plates 16 are coated with 20 µg/mL of 
fibronectin and allowed to incubate for 1 h.  HUVEC cells are prepared for the experiment by 
starvation in serum free media for 4 h.  After which, cells are detached and seeded onto the 
fibronectin coated CIM-Plates 16 at 15,000 cells/well. Cells are treated with PTX-M (0.2 nM), 
RAP-M micelles (0.2 nM), MIX-M (0.2 nM equivalent with PTX at 0.1 nM and RAP at 0.1 nM) or 
no treatment (control).  Migration from apical to the basolateral chamber containing complete 
growth medium is monitored every 10 min for 48 h.  Data for quadruplicate replicates is 
presented as mean cell index number ± SD. Statistical analysis using one-way ANOVA with 
Tukey’s post-test was conducted using GraphPad Prism version 6.07 for Windows, GraphPad 
Software, La Jolla California, USA. 
HUVEC endothelial tube formation assay was performed using matrigel coated µSlide 
Angiogenesis, ibiTreat plates.  Matrigel is thawed overnight in an ice bath (4 oC) and is then 
used to coat the wells at 50 µL/well.  Post coating, the wells are incubated at 37 oC for 60 
minutes to allow for gelation.  HUVECs are seeded at 20,000 cells/well and allowed to incubate 
at 37 oC for 18 h and cells are treated with PTX-M (0.2 nM), RAP-M micelles (0.2 nM) (C), MIX-
M (0.2 nM equivalent with PTX at 0.1 nM and RAP at 0.1 nM) or no treatment (control) for 10 h. 
After the experiment, the total tube length and area are measured using NIH ImageJ analysis 
software.  All experiments are performed in quadruplicate and representative images are 
presented.  
2.2.5. In vivo acute toxicity study in healthy mice  
Female nu/nu athymic mice 6-to-8 weeks old with an average weight of 20 to 22 g (Frederick 
National Laboratory for Cancer Research, Frederick, MD) are utilized to determine the acute 
toxicity of PTX-M, RAP-M and MIX-M.  Mice are separated into 5 groups with 5 mice per group 
(n = 25).  The groups include control (normal saline), PEG-LEV, PTX-M, RAP-M or MIX-M. Mice 
injected via tail vein at volumes corresponding to 80 -120 µL adjusted to the weight of each mice 
to ensure identical doses. The dose of the polymer or polymer and drug conjugate for PEG-
LEV, PTX-M, RAP-M or MIX-M are150 mg/kg, (corresponding to PTX or RAP or both drugs at 
60 mg/kg). The dose of 150 mg/kg (polymer-drug conjugate) was highest dose possible based 
on polymer solubility.  For the MIX-M, the dose of RAP and PTX were 30 mg/kg each (total drug 
dose of 60 mg/kg). The mice are injected on days 0, 4, and 8 and monitored for signs of acute 
toxicity, which include, changes in behavior, weight loss > 15%, or death over 21 days.  Data is 
presented as mean percent (%) normalized body weight ± SD.  All animal work is performed in 
compliance with NIH guidelines and Oregon State University IACUC Policy for End-Stage 
Illness and Pre-emptive Euthanasia, based on Humane Endpoints Guidelines. 
2.2.6. In vivo efficacy studies in ES2 murine xenograft model 
Female nu/nu athymic mice 6-to-8 weeks old with an average weight of 20 to 22 g (Frederick 
National Laboratory for Cancer Research, Frederick, MD) are implanted subcutaneously on the 
flank with ES2 at 1x106 cells to generate an ovarian cancer xenograft model. When the primary 
tumor volume reaches 150 to 200 mm3 (approximately 7-14 days), animals are randomized into 
5 groups (n = 25; 5/group). Each group is treated by lateral tail vain injections with the 
vehicle/control (normal saline), PEG-LEV, PTX M, RAP-M, or MIX-M. The volume of injection 
ranges between 80-120 μL as it is adjusted to the weight of each mouse to ensure identical 
doses.  The PEG-LEV is dosed at 50 mg/kg, while the micelles are dosed at 20 mg/kg of 
individual drugs or 10 mg/kg of each drug in the MIX-M (total amount of polymer injected 50 
mg/kg).  Mice are injected on days 0, 4, and 8 and tumor growth is assessed using a vernier 
caliper every 3 to 4 days. Tumor volumes are estimated by π/6 x length x width2. At the end of 
the experiments, % T/C values, (Δtumor volumetreated/Δtumor volumecontrol x 100) are calculated, 
where Δtumor volume represents the mean tumor volume on the test day minus the mean 
tumor volume at the start of the experiment. Mice are monitored for acute toxicity as defined by 
weight loss of ≥15% versus control, remarkable changes in general appearance, or death. Mice 
are euthanized at 21 days or when tumor volume reaches 3000 mm3. Tumor tissue is collected 
and samples are fixed in 4% paraformaldehyde overnight and embedded in paraffin blocks.  
Immunohistochemistry (IHC) studies using 5 µm section are performed as previously 
described.57  Anti-CD31 and anti-Cleaved Caspase-3 are used as primary antibodies to detect 
the density of the tumor-associated microvessels (angiogenesis) and apoptotic cells 
respectively.  Goat anti-rabbit CY3 is used as the secondary antibody (red).  Nuclei are 
counterstained with DAPI (blue).  All images are captured using a Zeiss AXIO ImagerZ1 with a 
digital AxioCam HRm and processed using AxioVision 4.7 (Carl Zeiss Microscopy, LLC) and 
Adobe Photoshop CS5 software. Cell quantifications are performed using NIH ImageJ software 
and multiple IHC fields on each slide from all groups are randomly chosen and at least 15 fields 
per group are counted. For apoptosis evaluation, the number of apoptotic cells positive to 
cleaved caspase 3 staining are counted in a minimum of 4 random fields (0.55 mm2, 20X 
magnification) per tumor section for 4 different tumors. The apoptotic index (%) is quantified 
using apoptotic cell number/total cell number x 100.  For angiogenesis evaluation, the CD31 
positive area percent (%) is calculated as CD31 positive area/total measured area x 100. At 
least 4 random fields (0.55 mm2, 20X magnification) per tumor section for 4 tumors are 
quantified to measure the CD31 positive area and calculate the % area as described above.  
All animal work is performed in compliance with NIH guidelines and Oregon State University 
IACUC Policy for End-Stage Illness and Pre-emptive Euthanasia, based on Humane Endpoints 
Guidelines. Statistical analysis for tumor volume is performed using one-way ANOVA at 5% 
significance level with Tukey’s Multiple Comparison post-test with groups compared at 5% 
significance level. Significance for immunohistochemistry is determined using one-way ANOVA 
at 5% significance level with Dunnett’s Multiple Comparison post-test with groups compared to 
control at 5% significance level. All statistical analyses are performed using GraphPad Prism 
software version 6.07 for Windows, GraphPad Software, San Diego, California USA.  
3. Results & Discussion 
3.1. Synthesis and characterization of PEG-p(Asp-Hyd-LEV-PTX) or PEG-p(Asp-Hyd-LEV-
RAP) 
The synthetic scheme for polymer-drug conjugations with PTX or RAP is depicted in Fig. 2.  The 
structure of PEG-PBLA (3) is confirmed by 1H NMR and the number of β-benzyl-L-aspartate 
units on PEG-PBLA is 40 (Fig.S1.) The polymerization of the PEG-PBLA is also confirmed by 
FT-IR spectroscopy which indicated the disappearance of two peaks corresponding to the BLA-
NCA (1850 and 1790 cm-1)(Fig.S4)58.  The Mn and the PDI of PEG-PBLA were 20, 200 g/mol 
and 1.19, respectively. PEG-HYD (4) is synthesized by an ester-amide exchange reaction, and 
its structure is confirmed by 1H NMR and FT-IR (Fig.S2 & Fig.S4 respectively). PTX and RAP 
lack an aldehyde or ketone functional group for hydrazone chemistry.  To address this issue we 
previously developed a polymer backbone that contains an aliphatic linker, LEV as a spacer 
group on PEG-HYD, to conjugate compounds that contain primary alcohol via ester bond. 41, 42  
PEG-LEV (5) is synthesized by a hydrazone bond formation between the hydrazide groups on 
PEG-p(Asp-Hyd) (4) and the ketone group on  LEV41, 42.  The number of LEV present in the 
PEG-LEV (5) is 40, corresponding to a 100% substitution and is confirmed by 1H NMR (Fig.S3) 
and the Mn(NMR & GPC), Mw, and PDI of the PEG-LEV are presented in Table 1.  PEG-LEV-
PTX (6) is synthesized by conjugation of PTX via an ester bond on PEG-LEV using a previously 
described method41, 42.  The structure of PEG-LEV-PTX polymer is confirmed by 1H NMR41, 42.  
The number of PTX molecules present in PEG-LEV-PTX (6) is 15 as calculated from 1H NMR 41, 
42 and GPC data (Table 1), corresponding to a 37.5% degree of drug substitution. The Mn(NMR 
& GPC), Mw, and PDI for the PEG-LEV-PTX are also presented in Table 1.  RAP is conjugated 
to the PEG-LEV polymer utilizing the same method as PTX conjugation. The structure of PEG-
LEV-RAP is also confirmed by 1H-NMR (Fig .3), FT-IR (Fig.S4) and GPC (Table 1). The number 
of RAP molecules present in PEG-LEV-RAP is 16 and is calculated from the peak ratio of the 
methylene protons of PEG (-OCH2CH2- : δ 3.5 ppm) (resonance b) to RAP methyl protons (3H 
-CH3- : δ 1.11 ppm) (resonance 45) (Fig.3), corresponding to a 40.0% degree of drug 
substitution. Ester prodrugs for RAP such as everolimus, temsirolimus, and deforolimus involves 
its C-40-OH position59 (Fig.3) however the position of RAP conjunction in PEG-LEV-RAP was 
not confirmed by 1H-NMR.  The Mn (NMR & GPC), Mw, and PDI for the PEG-LEV-RAP are 
presented in Table 1.  For the three polymers, the measured molecular weights from 1H NMR 
and GPC are in good agreement and based on the TEM images (Fig.S5.) and the calculated 
PDI values all of the polymers indicate a monodispersed population.   
 Fig. 3. 1H NMR spectra of PEG-LEV-RAP (6). NMR measurements are performed on a DPX-
400 NMR Spectrometer at 400 MHz in DMSO-d6 and at 80 oC. 
RP-HPLC measurements are used to confirm the absence of un-reacted PTX and RAP. RP-
HPLC analysis of the PEG-LEV-PTX resulted in a retention time of 1.30 min as detected by UV 
at its λmax of 227 nm as a single peak while free PTX elutes at 3.3 min.  Similarly, PEG-LEV-
RAP elutes at 2.00 min as detected at its λmax of 279 nm as a single peak, while free RAP elutes 
at 5.6 min.  Upon purification of the PEG-LEV-PTX or PEG-LEV-RAP no free PTX or RAP is 
detected. Based on RP-HPLC analysis the amount of the PTX per polymer is 0.38 g per 1 g of 
PEG-LEV-PTX, while the amount of RAP per polymer is 0.39 g per 1 g of PEG-LEV-RAP. 
Intrinsic viscosity [η] is specific property for a polymer that measures the polymer’s ability to 
increase the viscosity of a solvent, and it is used for determining the polymer size, molecular 
weight, and topology60. The [η] is related to the hydrodynamic radius, Rh, by the Flory-Fox 
expression61. Also [η] is related to molecular weight by the Mark-Houwink−Sakurada equation 
given as [η] = KMα, where M is the molecular weight while K and α are constants for a given 
polymer, solvent, and temperature. The  α value is strongly associated with the polymer rigidity 
and shape, for compact/spherical chains α < 0.5, for random-coil/flexible chain α usually lies in 
the range of 0.5-0.8, while α > 0.8 for rigid-rod/stiff chain 62. The [η], Rh and α values for PEG-
LEV, PEG-LEV-PTX and PEG-LEV-RAP are presented in Table 1. The [η] for the three 
polymers has different values inductive of different chemical and physical compositions resulting 
in different behaviors in the solvent system. PEG-LEV forms rigid chains (α of 1.9) with an Rh of 
6.6 nm. PEG-LEV-PTX polymer chains exist as random /flexible chains (α of 0.5) with an Rh of 
4.6 nm, while PEG-LEV-RAP forms compact spheres (α of 0.3) with an Rh of 4.7 nm. These 
data clearly indicate that the conjugations of the PTX or RAP to the PEG-LEV backbone results 
in the formation of two new polymer-conjugates that behave differently and form different 
secondary structures in a solvent system. 




















PEG-LEV 21,080 21,798 19,381 1.13 ------ 0.1558 6.6 1.9 
PEG-LEV-PTX 33,620 35,081 30,042 1.17 15 0.1793 4.6 0.5 
PEG-LEV-RAP 35,432 36,353 28,568 1.27 16 0.2154 4.7 0.3 
 
a Determined by 1H NMR 
b Determined by GPC, Triple detection method, calibration was established with narrow PMMA 
standard, DMF with 10 mM LiBr 
c Determined by: (Mw (PEG− LEV− Drug)− Mw (PEG− LEV)) ⁄ Mw (drug) 
 
3.2. Preparation and characterization of PTX-M, RAP-M, and MIX-M 
RP-HPLC indicates that PTX-M and RAP-M has 4.4 µmol of PTX and 4.3 µmol of RAP per 1 mL 
of micellar solution.  In the case of the MIX-M, 2.4 µmol PTX and 2.2 µmol of RAP are present 
in 1 mL of micellar solution. DLS is used to determine the particle size of freshly prepared PTX-
M, RAP-M, and MIX-M. All micelles exhibited monodisperse population.  The size of PTX-M, 
RAP-M, and MIX-M are 41.9 ± 0.6 nm (PDI = 0.112 ± 0.005), 90.1 ± 2.1 nm (PDI = 0.128 ± 
0.023), and 102.3 ± 3.5 nm (PDI = 0.138 ± 0.009) respectively.  The spherical shape and 
monodispersity of the micelles are further confirmed by TEM measurements (Fig.S5). The larger 
size of the RAP-M compared to PTX-M for the same polymer backbone is possibly due to 
differences in the packing of the micelles core and this speculation is supported by the Mark-
Houwink Constants α values (Table 1) that PEG-LEV-PTX and PEG-LEV-RAP polymers chains 
exist in different conformations in polar solvents such as DMF and water.  This effect has been 
also documented elsewhere where changes in the hydrophobicity of the core can have 
significant impact on micelle packing, size, and stability63. The sizes for MIX-M and RAP-M are 
similar, indicating that the RAP packing has a greater impact on the overall size of the micelle.   
Release of the conjugated drug(s) from the micelles over 24 h was performed under sink 
conditions at pH 7.4 (mimicking physiological pH), and pH 5.5 (mimicking acidic conditions 
associated with the endosomal/lysosomal pathway of cells)52-54, 64.  The release data for the 
PTX-M, RAP-M, and MIX-M along with their respective fitted curves is presented in (Fig.4). As 
seen in the drug release profile, the release of the drug from the polymer backbone is greater at 
pH 5.5 as compare to pH 7.4. This is expected as the hydrazone linker, LEV, is cleaved from 
the polymer backbone at acidic pH42, 52-54, 64. The drugs release profile for the individual and 
mixed micelles did not reach 100% within 24 h, suggesting that some of the hydrazone bonds 
have not been cleaved during the experimental time frame. Our findings are in agreement with 
previous studies42, 43. Nonlinear curve fitting using a one phase exponential association 
indicates that a good fit is achieved at pH 5.5 but not at pH 7.4.  At pH 5.5 the t1/2 and r2 values 
for the fitting for PTX-M are 6.85 h and 0.9782 respectively, while at pH 7.4, no t1/2 could be 
calculated and with r2 value of 0.8924 (Fig. 4A).  As the major step in the drug release is the 
cleavage of the linker from the polymer backbone, it is not surprising that at pH 7.4 minimal 
release occurs, and therefore, curve fitting is ambiguous for PTX in PTX-M.  Interestingly, RAP-
M release data at both pHs could be curve fitted using the one phase exponential association.  
The t1/2 and r2 values for RAP-M at pH 5.5 are 2.34 h and 0.9173, while at pH 7.4 it is 2.60 h and 
0.9554 respectively.  However, as seen in Fig.4B the rate of RAP release from RAP-M is much 
slower, with only ~30% of the RAP released in 24 h at pH 7.4 versus ~60% release at pH 5.5.  
In the case of the MIX-M (Fig. 4C), the release patterns for both drugs at both pHs changes 
indicating that the packing of the drug conjugated polymers is different in these micelles.  The 
t1/2 and r2 values for PTX in MIX-M at pH 5.5 are 0.87 h and 0.9484, respectively, while for RAP 
these values are 0.92 h and 0.9121 respectively.  At pH 7.4, the t1/2 and r2 values for PTX in 
MIX-M are 0.31 h and 0.5685 respectively, while for RAP these values are 1.12 h and 0.7420.  
This data shows the release profile for PTX and RAP from MIX-M is also dependent on the pH 
and it is higher at pH 5.5. Interestingly, the release profile of PTX and RAP are nearly identical 
pH 7.4 but show slight differences in the extent of release at pH 5.5 (Fig. 4C). The release 
profile of PTX and RAP from individual and MIX-M is not the same and it is clearly depended on 
the composition and the core properties of the polymeric micelle.
 
Fig.4. Release of PTX and/or RAP from PTX-M (A), RAP-M (B), and MIX-M (C) at pH 5.5 & 7.4 
under sink conditions (37 °C, n=3).  The solid lines represent the nonlinear curve fitting of the 
data using a one phase exponential association. 
3.3. In vitro cell viability and combination index analysis studies in SKOV-3, ES2, and 
HUVEC cells 
Prior to the initiation of animal studies, cell-based viability studies were performed in two ovarian 
cancer lines (SKOV-3 and ES2) and in an endothelial cell line (HUVEC).  The IC50 values for 
each of the micelles in all three cell lines are presented in Fig.5.(A-C) and the IC50 values for the 
free drugs and their combination are presented in Fig.S6.  The IC50 of PTX-M and RAP-M in all 
the cell lines are in nM range indicating the strong anti-proliferative effect of each of the drugs in 
their respective micelles. The IC50 of the MIX-M irrespective of the cell line, demonstrated 
greater potency than either of the individual micelles, further analysis to determine the nature 
and the degree of interaction was performed using CI analysis.  The CI analysis (Fig. 5D) 
indicates that for all three cell lines the MIX-M containing PTX and RAP are synergistic (CI < 1) 
at all fractions of cells affected (Fa). Comparing the anti-proliferative effect of the free drug and 
micelles, PTX is slightly more potent than PTX-M in the SKOV-3 and HUVEC cell lines, while 
free RAP is significantly less potent than RAP-M in all three cell lines as indicated by the higher 
IC50. We speculate the reason behind that is RAP-M increased the solubility of RAP significantly 
thereby producing a stronger inhibition on cell viability. CI analysis indicates that in all three cell 
lines at lower fractions affected the free drugs are synergistic but become antagonistic at higher 
fractions of cells affected (Fig.S6) unlike the MIX-M which remains synergistic at all fractions 
affected.        
PTX is a mitotic inhibitor that stabilizes microtubules while RAP inhibits the activation of the 
mammalian Target of Rapamycin (mTOR)59, 65, 66. Thus, the dual mechanisms of actions of the 
two drugs, acting together, decrease the ability of the cell to overcome the cytotoxic effects. Our 
findings are in agreement with the findings of others who showed that RAP potentiates the 
cytotoxicity of taxanes in different cancer cell lines. Liu et al. showed that in two prostate cancer 
cell lines RAP acts synergistically with docetaxel by enhancing docetaxel-induced upregulation 
of caspase activity through cell cycle arrest in sub-G1 phase67. In another study, the effect of 
RAP and PTX combination on two ovarian cancer cell lines, SKOV-3 and A2780, is assessed 
and the two compounds act synergistically to inhibit cell proliferation, induce cell apoptosis, and 
down-regulate the expression of survivin68. The same combination of RAP and PTX when 
evaluated in endometrial cancer cells demonstrated similar findings with the PTX and RAP 
combination synergistically inhibiting cell proliferation and inducing cell apoptosis69.  The anti-
proliferative effect of PTX-M, RAP-M, and MIX-M against HUVEC cells is also in agreement with 
our previous work in which PTX and RAP loaded in PEG-b-PLA micelles inhibited HUVEC cell 
proliferation and their combination acts synergistically. In addition, others have demonstrated 
that both PTX and RAP individually inhibits the proliferation of HUVEC at nM concentrations28, 
29.          
 Fig. 5. IC50 values for PTX-M, RAP-M, and MIX-M in ES2 cells (A), SKOV-3 cells (B), and 
HUVEC (C); Fa vs CI plots for MIX-M in ES2 cells, SKOV-3 cells, and HUVEC (D). Error bars 
represent (Mean ± SD, n=4).  
3.4. In vitro real-time migration and tube formation studies in HUVECs 
As both, PTX and RAP, individually have the ability to inhibit the angiogenic cascade processes 
of proliferation, migration, and tube formation22, 23, 33 in this study we wanted to assess the 
efficacy of these drugs in the individual and mixed micelles.  Two aspects of angiogenesis 
processes, migration and tube formation, are assessed using HUVEC.  The treatment groups in 
both experiments were HUVEC left untreated (control), treated with 0.2 nM of PTX, RAP in 
individual micelles or 0.1 nM of each in MIX-M.  PTX-M and RAP-M concentrations selected for 
the studies were below the IC50 values in HUVEC of the micelles (Fig.5).  This selection was 
based on earlier findings that PTX and RAP inhibit endothelial migration and tube formation at 
much lower doses than their IC5033, 70. Data from the migration assay is presented in Fig. 6A.  As 
seen in the data, the migration of HUVEC significantly decreased over 48 h as compared to 
control cells when treated with PTX-M, RAP-M, or MIX-M.  No significant differences were noted 
in the migration upon comparing PTX-M, RAP-M, or MIX-M. Cell migration process is regulated 
through reorientation of centrosome in the intended direction of movement71. A change in 
microtubule plasticity can also alter the reorientation of the centrosome71. Based on these 
mechanisms, and our data, we postulate that PTX-M, RAP-M and MIX-M interfere with these 
processes and thereby inhibit cell migration.  
In the tube formation assay, at 18 h, post-treatment images were obtained to ascertain the 
degree of tube formation.  A representative set of these images is presented in Fig. 6B. As seen 
in the figure, control cells (I) have the highest degree of tube formation followed by PTX-M (II) or 
RAP-M (III), and then the MIX-M(IV).  In the case of the MIX-M the tube formation seems to be 
highly disrupted again indicating that the conjugation of the drugs to the polymer backbone does 
not interfere with the anti-angiogenic activity of PTX and RAP and synergistic effects are not 
lost.  Endothelial tube formation involves multiple steps such as attachment and migration prior 
to the tube formation process. Tube formation is initiated with attachment of endothelial cells on 
the basement matrix and then is followed by migration of these cells toward each other to 
eventually form tubes72. Our data has shown these process can be inhibited at concentrations 
well below the IC50 value of PTX-M and RAP-M and MIX-M (Fig. 6). It was reported that PTX 
and other taxanes cause cell cycle arrest in S phase or G1/S phase at lower concentrations, 
which is primarily responsible for inhibiting the tube formation process70. RAP and other mTOR 
inhibitors effect VEGF expression and block the endothelial transition to mesenchymal29. In 
MIX-M significant inhibition of HUVEC tube formation was observed presumably due to PTX 
and RAP acting on different pathways in the endothelial cells to produce a synergistic effect. 
This assumption is based on previous findings in which RAP has the ability to potentiate the 
effect of PTX and docetaxel through inhibition of cancer cell proliferation and induction of 
apoptosis67, 69.  In addition, Mishra et al. showed that RAP produces antiangiogenic effects and 
acts synergistically with PTX to inhibit the angiogenic cascade processes of proliferation, 
migration, and tube formation33. These finding are further confirmed in our work in which we 
have shown that MIX-M affects angiogenesis by inhibiting HUVEC cells proliferation, migration, 
and tube formation (Figs. 5 and 6). Based on the cell viability, migration, and tube formation 
assays, the individual and mixed micelles offer the capability to use these conjugated micellar 
systems for targeting cancer cells or angiogenesis, thus, providing a versatile platform for 
various treatment options.  
  
Fig. 6. Real-time cellular migration profile (RTCM) for HUVEC cells treated with: PTX-M 0.2 nM, 
RAP-M 0.2 nM, or MIX-M 0.2 nM (PTX 0.1 nM and RAP 0.1 nM), *Represents significant 
difference from untreated control. (Mean ± SD, n=4, α=0.05, 95% confidence intervals) (A); 
Tube formation assay:Control(I), PTX-M 0.2 nM (II), RAP-M micelles 0.2 nM (III), MIX-M 0.2 nM 
(PTX 0.1 nM and RAP 0.1 nM) (IV) (B). *Represents significant difference from control (saline) 
(Mean ± SD, n=4). Significant differences between treatment group means were evaluated 
using one way ANOVA with Dunnett’s Multiple Comparison Test (compare all columns vs. 
control) using a significant level (α) of 0.05. Analysis was performed with GraphPad Prism 
version 6.07 for Windows, GraphPad Software, San Diego, California USA,  
3.5. In vivo acute toxicity study in healthy mice 
Female nu/nu athymic mice are used to determine the acute toxicity due to treatment with the 
PEG-LEV, PTX-M, RAP-M, or MIX-M.  Post-injection, mice were monitored for 21 days for 
changes in behavior, weight loss > 15 % and death.  During the course of the study none of the 
mice treated exhibited any changes in behavior or died.  Weight changes between the treatment 
and control (saline treated) groups is presented in Fig. 7.  As seen in Fig. 7 none of the mice in 
the treatment groups are significantly different as compared to the control mice, indicating that 
treatment at such high concentrations with the drug(s) at (60 mg/kg/drug) have no adverse 
effects. Currently PTX is commercially available as Taxol® (Cremophor® EL-Ethanol formulation) 
and AbraxaneTM (nanoparticles albumin-bound PTX).  The MTD for PTX is highly dependent on 
the formulation. For example Taxol MTDs in mice range from 20-30 mg/kg/injection (i.v., every 2 
days for 5 cycles)73. While the MTD for Abraxane in mice is 120 mg/kg (i.v., every fourth day for 
3 cycles) 74. Cynviloq™ (under clinical trials) is another formulation of PTX (PEG-b-PLA micelle 
physically loaded with PTX) has MTD of 50 mg/kg (i.v, every day for three days)75, 76. In 
comparison PTX-M showed no acute toxicity at a dose higher than Taxol® and comparable to 
Cynviloq™.     
Currently there is no commercially available parenteral formulation for RAP. The MTD for RAP 
is 5 mg/kg/day I.P. injection for 5 consecutive days for 6 weeks where RAP is formulated in 5% 
DMSO, 5% Tween 80 in water77. Therefore RAP-M is a viable intravenous formulation for RAP 
and shows excellent safety. Interestingly, MIX-M showed non-additive acute toxicity in mice, 
indicating that such platform can be utilized for the co-delivery of PTX and RAP at clinically 
relevant concentrations.  Shin et al. demonstrated the PTX and RAP co-delivered in PEG-b-PLA 
micelle at 60 mg/kg and 30 mg/kg respectively showed no acute toxicity in mice45. In 
comparison MIX-M was able to deliver PTX and RAP at 30 mg/kg each safely.   
 Fig. 7. Normalized body weight of mice over time after i.v. injection of PEG-LEV, PTX-M, RAP-
M, and MIX-M on days 0, 4, and 8 as indicated by arrows. PEG-LEV (A), PTX-M at 60 mg/kg of 
PTX (B), RAP-M at 60 mg/kg of RAP (C), MIX-M at total drug 60 mg/kg (D) (30 mg/kg of PTX + 
30 mg/kg of RAP) (n = 5/treatment, Mean ± SD). Mice were injected with saline as negative 
control. The horizontal dashed line in all figures represents loss in weight ≥ 15% body weight as 
an indication of toxicity.  
3.6. In vivo efficacy studies in ES2 murine xenograft model 
Individual and mixed micelle efficacy in treating ovarian cancer is evaluated in an ES2 xenograft 
model. Mice are treated at 20 mg/kg of individual drug or 10 mg/kg of each drug in MIX-M on 
day 0, 4, and 8, and tumor growth is assessed for 21 days post-treatment. As the dose-limiting 
toxicity DLT and MTD value could not be determined due to the limitation of the polymer-drug 
conjugate solubility (section 2.2.5). A lower dose and more frequent administration schedule of 
3 doses every four days instead of one dose at MTD every 2-3 weeks is chosen to assess the 
cytotoxic and anti-angiogenic effect of the individual and mixed micelles.  The lower dose with a 
greater frequency of administration mimics a MR dosing.  
Tumor volumes (Fig. 8A), caspase-3 activity (Fig. 8B & 9A) and the density of blood vessels in 
the tumor tissue (Fig. 8C & 9B) are presented to demonstrate efficacy and mechanisms of 
action. The data presented in Fig 8A indicates that the PEG-LEV (polymer backbone) has no 
effect on the tumor volume and it is not significantly different from the saline treated group, 
indicating that the polymer itself has no effect on tumor tissue.  The tumor volumes for PTX-M 
and RAP-M, are smaller after 21 days as compared to saline or PEG-LEV, however no 
statistical difference is seen between the individual micelles and saline (Fig. 8A).  MIX-M treated 
group produced significant reduction in tumor volume after 21 days as compared to the saline 
treated group. The highest reduction in tumor volume is seen in the MIX-M group, confirming 
the synergistic effects seen in the cell culture work.   
To determine the effect of individual and mixed micelles on the ES2 xenograft, apoptosis 
induction and angiogenesis inhibition within the tumor tissue, are also evaluated and presented 
in Fig.8 & 9. Cleaved Caspase-3 assay is used to quantify the apoptotic activity as caspase-3 is 
a critical executioner of apoptosis and is either partially or fully responsible for the proteolytic 
cleavage of many key proteins within the cells78. Visually the IHC staining of the tumor tissue 
with the anti-Caspase-3 antibody (Fig. 9A) clearly indicates a higher density of apoptotic cells in 
the MIX-M group compared to the saline and PEG-LEV groups. Upon quantification, it is seen 
that only the MIX-M showed significant induction of apoptosis in the tumor tissue as compared 
to control (Fig. 8B & 9A). Thus, the tumor volume reduction with MIX-M is at least partially due 
to the induction of apoptosis that seems to occur due to the synergistic effects of PTX and RAP. 
Interestingly, all micelles, PTX-M, RAP-M, and MIX-M, significantly inhibited angiogenesis 
formation within the tumor tissue as compared to saline (Fig. 8C & 9B). This inhibition is 
represented by the reduction in the of CD31 expression, which is a marker for endothelial cells 
(Fig. 9B).  Further comparison between the micelle groups indicates that the MIX-M treated 
group has reduced the blood vessel density within the tumor region as compared to PTX-M and 
RAP-M (Fig 8C). Thus, in the case of MIX-M the tumor volume reduction is also driven by the 
inhibition of the angiogenesis, while in the case of the individual micelles, at these 
concentrations only angiogenesis inhibition occurs but no cytotoxic effects are seen. The ability 
of PTX and RAP to induce an antiangiogenic effect is well documented in the literature and 
many studies have shown that the endothelial cells and neovasculature are sensitive to these 
agents at concentrations lower than that required for cancer cells18, 22, 33. Clearly the PTX-M and 
RAP-M follow the same pattern at 20 mg/kg to produce antiangiogenic effects without apoptosis 
induction in the tumor tissue. Thus, based on our data we can use these individual micelles in a 
frequent dosing schedule and at a lower dose to target the tumor microenvironment instead of 
the cancer cells.  We anticipate at higher doses and/or more frequent dosing both PTX-M and 
RAP-M will induce apoptosis as both compounds can produce such effects at specific doses in 
in vitro and in vivo models 79, 80. MIX-M, however, showed duel antiangiogenic and apoptosis 
inducing effects leading to greater reduction in the tumor volume in comparison to saline, PEG-
LEV, and individual micelles.  
 
 Fig. 8. Xenograft regression in mice over time after i.v. injection of saline (control), PEG-LEV, 
PTX-M, RAP-M, MIX-M at PTX and/or RAP at 20 mg/kg each on days 0, 4, and 8 as indicated 
by arrows (n = 5/treatment, Mean ± SD). Tumor volume (A), quantification of apoptotic cells in 
tumor tissue by counterstaining with anti-Caspase-3 antibody (B), quantification of microvessel 
in tumor tissue by counterstaining with anti-CD31 antibody (D31 positive) (C). * Represents 
significant difference from control (saline), # represents significant difference from MIX-M (Mean 
± SD, n=5). Significant differences between treatment group means is evaluated using one way 
ANOVA with Dunnett’s Multiple Comparison Test (compare all columns vs. control) or 
Bonferroni Multiple Comparison Test (compare all pairs of columns) using a significant level (α) 
of 0.05. Analysis is performed with GraphPad Prism version 5.04 for Windows, GraphPad 
Software, San Diego California USA 
 
  
Fig. 9. ES2 ovarian cancer xenograft mice treated with saline (i), PEG-LEV (ii), PTX-M (iii), 
RAP-M (iv), and MIX-M (v). IHC staining for tumor-associated apoptotic cells (A) and 
Angiogenesis (B). Apoptotic cells are identified by counterstaining with anti-Caspase-3 antibody 
(red). Endothelial cells (angiogenesis) are identified by counterstaining with anti-CD31 antibody 
(red). Cells Nuclei are identified with DAPI staining (Blue).    
Conclusions 
Current chemotherapeutic strategies of dosing at MTD to treat solid tumors like ovarian cancer 
every 3 weeks 3, 4 allow the patient to recover from chemotherapy-induced adverse effects.  
However, this drug-free interval can promote tumor to reinitiate growth5 through the mobilization 
of circulating endothelial progenitor cells and results in tumor neovascularization3.  The MTD 
chemotherapy in general is effective in cancers without a complex network of activating 
mutations such as gestational choriocarcinomas, testicular cancer, Hodgkin’s disease, and B-
cell non-Hodgkin’s lymphoma81. Complex cancers such as ovarian, sarcoma, breast, prostate, 
and lung demonstrate poorer prognosis with conventional MTD treatment regimens81.  New 
advances in tumor biology suggest targeting the tumor microenvironment and not just the 
cancer cells through anti-angiogenic agents and reactivating host immune responses may 
provide better outcomes in complex cancers20. Targeting angiogenesis is one of the corner 
stones of MR. Recent studies have shown that MR induces other mechanisms of actions 
including antitumor immune response and direct anticancer effects. Therefore, MR is now 
considered to be a form of multiple-targeted chemotherapy that has a profound effect on the 
tumor microenvironment. Conjugated micelles offer the ability to elicit multiple mechanisms of 
action for a drug which may be suppressed in conventional dosage forms. In our study, we have 
demonstrated, in vitro and in vivo, the safety and efficacy of the conjugated PTX, RAP, or PTX 
and RAP 1:1 mixed micelles in treating ovarian cancer through both cytotoxic effects in cancer 
cells and simultaneous inhibition of angiogenesis. Thus, offering a drug delivery system that can 
be tailored to different treatment paradigms like MTD dosing or MR.  In addition, the MIX-M, 
through its synergistic activity, may also prove to be more effective in overcoming resistance 
issues commonly seen with other chemotherapeutic agents. Thus, the MIX-M micellar system 
can provide a platform that will allow clinicians to tailor therapy to tumor cells or the tumor 
microenvironment for the treatment of complex cancers like ovarian cancer. 
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